Why Automation is Key for Life Sciences Companies Transitioning from R&D to Clinical Trials

As an industry leader at Sikich, I’ve seen firsthand how life sciences companies often find themselves grappling with the complexities of transitioning from research and development (R&D) to clinical trials. This move is crucial, and it’s where automation can play a game-changing role.

Let’s dive into why automation is so essential during this phase and how it can help streamline operations, reduce errors, and drive efficiency.

The Challenge of Transitioning from R&D to Clinical Trials

Life sciences companies usually start with a small team of brilliant scientists and researchers who focus intensely on developing new medications. During the early stages, much of the company’s energy is directed towards R&D, which makes sense. After all, without innovation, there would be no new therapies to bring to market. However, as these companies progress from Phase I to Phases II and III of clinical trials, they often find that their initial, fragmented technology systems just can’t keep up.

At this point, the need for a more robust infrastructure becomes glaringly obvious. The processes that worked during the R&D phase—like using basic spreadsheets or standalone systems—start to create bottlenecks and inefficiencies. This is where automation steps in as a critical solution.

How Automation Streamlines the Process

Automation can help life sciences companies manage the complex and regulated processes involved in clinical trials. By automating routine tasks and data management, companies can reduce the likelihood of human error, which is especially important in an industry where mistakes can have serious consequences.

For example, Sikich’s SuiteSuccess for Life Sciences, built on NetSuite, allows companies to automate many of their operational workflows, from financial reporting to regulatory compliance. This automation helps maintain accuracy and ensures that companies can scale their operations quickly without adding many staff members. As Mike Kean, Partner-in-Charge of Sikich’s technology team, points out, “With NetSuite in place, growing life sciences firms can overcome challenges such as manual processes that cannot scale and implementing financial controls.”

Reducing Time and Costs with Automation

Another significant advantage of automation is the potential for cost savings. Clinical trials are notoriously expensive and time-consuming. According to our data, it currently takes around 12 years and $1.25 billion to bring a therapy from discovery to commercialization. Automating data management and reporting processes can cut down on these costs and reduce the time it takes to get through clinical trials.

By integrating automation into their operations, life sciences companies can also better manage their cash flow and spending, which is crucial when they are not yet generating revenue. Automation ensures that processes are handled consistently and efficiently, reducing the need for manual intervention and enabling teams to focus on more strategic tasks.

The Path Forward

As life sciences companies continue to innovate and push the boundaries of what’s possible in drug development, automation will be a key enabler of their success. By streamlining operations and reducing the risk of errors, automation allows these companies to navigate the complex transition from R&D to clinical trials more smoothly and efficiently.

At Sikich, we’re committed to helping life sciences companies leverage the power of automation through solutions like SuiteSuccess for Life Sciences. Whether you’re just starting out or preparing for an IPO, our team is here to support you every step of the way. Let’s make sure your technology infrastructure is as cutting-edge as your science. Contact us today!